SAM #PANHCA-26-P-0000-026886

Lease of Molecular MRSA Analyzer for William Beaumont Army Medical Center (Sole Source to Cepheid)

This opportunity is for the lease of a Molecular MRSA analyzer to support the Department of Pathology at William Beaumont Army Medical Center (WBAMC), Fort Bliss, Texas. - The US Army Health Contracting Activity intends to award a sole source, firm-fixed-price lease contract to Cepheid, Inc. - The analyzer must support multiple tests: - MRSA (Methicillin-Resistant Staphylococcus aureus) - Influenza A/B - RSV (Respiratory Syncytial Virus) - SARS-CoV2 - Strep A - Mycobacterium Tuberculosis - Carbapenem - The lease includes maintenance, troubleshooting, replacement, and software support for the analyzer. - Cepheid is the only FDA-approved vendor meeting the requirements, with proprietary technology and exclusive consumables. - The contract period is five years: one base year (Oct 1, 2026 - Sep 30, 2027) plus four one-year options (through Sep 30, 2031). - Other vendors may submit capability statements if they can provide a comparable analyzer on a lease basis. - No specific part number or model is provided. - The procurement is structured as a lease, not a purchase. - Estimated contract value is likely in the range of $150,000 to $350,000 for the five-year period.

Key Details: - Agency: Department of the Army, William Beaumont Army Medical Center - OEM: Cepheid, Inc. - Quantity: 1 analyzer - Lease includes full support and maintenance - Sole source justification based on proprietary technology and FDA approval - Opportunity for other vendors to respond with capability statements

Description

On or about 31 July 2026, the Medical Readiness Contracting Officer- West intends to issue a sole source contract to Cepheid for a non-personal service contract for lease of Molecular MRSA analyzer to support William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX. The period of performance is 01 October 2026 to 30 September 2031. This notice is neither a request for quotes nor a solicitation of offers; however, all responsible sources may submit a capability statement, which shall be considered by the agency. The capability statement shall include information of suicient detail to demonstrate that they are able to provide a non-personal service contract for the lease of Molecular MRSA analyzer. 

View original listing